-Paul W Manley Researcher Activity Profile

Research Author Detailed Information 

Paul W Manley Publication Rate By Year

Paul W Manley has published 1 paper(s) in 2006, 8 paper(s) in 2007, 1 paper(s) in 2008, for a total of 10 research publications in total.

Paul W Pw Manley Author Information

LAST NAME: manley

FIRST NAME: Paul W

INITIALS: pw

AFFILIATION:

Papers

Paul W Manley's Publication Record

1. Effects of PKC412, nilotinib, and imatinib against GIST-associated PDGFRA mutants with differential imatinib sensitivity. Year Published: 2006
Department of Medical Oncology, Dana Farber Cancer Institute, Boston, Massachusetts 02115, USA. Ellen_weisberg@dfci.harvard.edu
2. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Year Published: 2007
3. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Year Published: 2007
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
4. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Year Published: 2007
Department of Internal Medicine I, Division of Hematology & Hemostaseology, Medical University of Vienna, Vienna, Austria.
5. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Year Published: 2007
Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, Australia. deb.white@imvs.sa.gov.au
6. Inhibition of the human P2X(7) receptor by a novel protein tyrosine kinase antagonist. Year Published: 2007
Department of Medicine, Nepean Clinical School, University of Sydney, Penrith, NSW, Australia.
7. Inhibition of the human P2X7 receptor by a novel protein tyrosine kinase antagonist. Year Published: 2007
Department of Medicine, Nepean Clinical School, University of Sydney, Penrith, NSW, Australia.
8. Most CML patients who have a suboptimal response to imatinib have low OCT-1 activity: higher doses of imatinib may overcome the negative impact of low OCT-1 activity. Year Published: 2007
Division of Haematology, Institute of Medical and Veterinary Science, Adelaide, Australia. deb.white@imvs.sa.gov.au
9. Inhibition of the human P2X7 receptor by a novel protein tyrosine kinase antagonist. Year Published: 2007
Department of Medicine, Nepean Clinical School, University of Sydney, Penrith, NSW, Australia.
10. Comparison of nilotinib and imatinib inhibition of FMS receptor signaling, macrophage production and osteoclastogenesis. Year Published: 2008